Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug excipients

This article was originally published in The Tan Sheet

Executive Summary

Microcrystalline cellulose (MCC) suppliers FMC Corp. and Asahi Chemical Industry reach proposed consent agreements settling FTC charges that they conspired to divide territories for sale of, and control the world market for, MCC, a binding agent found in nearly all drug tablets sold in the U.S. FTC also alleges Chicago-based FMC, the world's largest manufacturer and seller of MCC, invited smaller rivals to collude. Under the proposed orders, FMC and Japanese firm Asahi would be barred from agreeing with competitors to allocate markets for, or refrain from selling, the ingredient. FMC also would be barred for 10 years from acting as U.S. distributor for any competing MCC manufacturer
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel